AR005724A1 - Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple - Google Patents
Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multipleInfo
- Publication number
- AR005724A1 AR005724A1 ARP970100464A ARP970100464A AR005724A1 AR 005724 A1 AR005724 A1 AR 005724A1 AR P970100464 A ARP970100464 A AR P970100464A AR P970100464 A ARP970100464 A AR P970100464A AR 005724 A1 AR005724 A1 AR 005724A1
- Authority
- AR
- Argentina
- Prior art keywords
- multiple sclerosis
- treatment
- biologically active
- compound
- ureid
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000013543 active substance Substances 0.000 abstract 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000542 sulfonic acid group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se refiere a la utilización de un compuesto que es un derivado ureído de fórmula (I), en donde cada m y n, que son lo mismo, es un entero de 1 a 3, ycada uno de los grupos R, que son lo mismo, es un grupo naftilo substituido por 1 a 3 grupos de ácido sulfónico, o una sal farmacéuticamente aceptabledel mismo, en la elaboración de un medicamento para ser utilizado en el tratamiento de la esclerosis múltiple. También se refiere a productos quecontienen dicho compuesto y otro agente biológicamente activo como una preparación combinada para ser empleada en forma simultánea, separada osecuencial en el tratamiento de pacientes que padecen esclerosis múltiple, a un método para tratar un paciente que padece de esclerosis múltiple, el cualconsiste en administrar al paciente una cantidad efectiva de dicho compuesto, ya sea en forma separada o substancialmente simulténea, dicho compuesto yotro agente biológicamente activo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9602721.4A GB9602721D0 (en) | 1996-02-09 | 1996-02-09 | Biologically active ureido derivatives useful in the treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR005724A1 true AR005724A1 (es) | 1999-07-14 |
Family
ID=10788461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970100464A AR005724A1 (es) | 1996-02-09 | 1997-02-06 | Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5859046A (es) |
| EP (1) | EP0820284B1 (es) |
| JP (1) | JPH11504041A (es) |
| KR (1) | KR19980703718A (es) |
| AR (1) | AR005724A1 (es) |
| AT (1) | ATE189388T1 (es) |
| AU (1) | AU1720097A (es) |
| BR (1) | BR9702075A (es) |
| CA (1) | CA2217008A1 (es) |
| DE (1) | DE69701243T2 (es) |
| DK (1) | DK0820284T3 (es) |
| EA (1) | EA000166B1 (es) |
| ES (1) | ES2144844T3 (es) |
| GB (1) | GB9602721D0 (es) |
| GR (1) | GR3033332T3 (es) |
| HU (1) | HUP9900796A2 (es) |
| IL (1) | IL121808A0 (es) |
| NO (1) | NO974651L (es) |
| PL (1) | PL322717A1 (es) |
| PT (1) | PT820284E (es) |
| WO (1) | WO1997028796A1 (es) |
| ZA (1) | ZA97902B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1711499A (en) * | 1997-12-04 | 1999-06-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds or inhibition of inflammation |
| GB9727524D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Synergistic antitumor composition containing a biologically active ureido compound |
| US6348464B1 (en) * | 1999-11-12 | 2002-02-19 | Guilford Pharmaceuticals, Inc. | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
| ATE433445T1 (de) | 2003-03-03 | 2009-06-15 | Eisai Corp North America | Thiolactone als naaladase inhibitoren |
| EP3381897A1 (en) | 2017-03-27 | 2018-10-03 | Leadiant Biosciences SA | Derivatives of the disodium 2,2'-{carbonylbis[imino-3,1-phenylenecarbonylimino(1-methyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalene-1,5-disulfonate salt and related compounds as heparanase inhibitors for the treatment of cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9304589D0 (en) * | 1993-03-05 | 1993-04-21 | Erba Carlo Spa | Biologically active ureido derivatives useful as antimetastic agents |
| GB9307948D0 (en) * | 1993-04-16 | 1993-06-02 | Erba Carlo Spa | Biologically active ureido derivatives useful in the treatment of lentivirus-induced disease |
-
1996
- 1996-02-09 GB GBGB9602721.4A patent/GB9602721D0/en active Pending
-
1997
- 1997-01-24 KR KR1019970707118A patent/KR19980703718A/ko not_active Withdrawn
- 1997-01-24 DK DK97904356T patent/DK0820284T3/da active
- 1997-01-24 ES ES97904356T patent/ES2144844T3/es not_active Expired - Lifetime
- 1997-01-24 AU AU17200/97A patent/AU1720097A/en not_active Abandoned
- 1997-01-24 JP JP9528110A patent/JPH11504041A/ja active Pending
- 1997-01-24 PL PL97322717A patent/PL322717A1/xx unknown
- 1997-01-24 AT AT97904356T patent/ATE189388T1/de not_active IP Right Cessation
- 1997-01-24 BR BR9702075A patent/BR9702075A/pt not_active Application Discontinuation
- 1997-01-24 WO PCT/EP1997/000412 patent/WO1997028796A1/en not_active Ceased
- 1997-01-24 CA CA002217008A patent/CA2217008A1/en not_active Abandoned
- 1997-01-24 EA EA199700302A patent/EA000166B1/ru not_active IP Right Cessation
- 1997-01-24 HU HU9900796A patent/HUP9900796A2/hu unknown
- 1997-01-24 DE DE69701243T patent/DE69701243T2/de not_active Expired - Fee Related
- 1997-01-24 US US08/930,598 patent/US5859046A/en not_active Expired - Fee Related
- 1997-01-24 PT PT97904356T patent/PT820284E/pt unknown
- 1997-01-24 EP EP97904356A patent/EP0820284B1/en not_active Expired - Lifetime
- 1997-01-24 IL IL12180897A patent/IL121808A0/xx unknown
- 1997-02-04 ZA ZA9700902A patent/ZA97902B/xx unknown
- 1997-02-06 AR ARP970100464A patent/AR005724A1/es unknown
- 1997-10-08 NO NO974651A patent/NO974651L/no unknown
-
2000
- 2000-04-26 GR GR20000401016T patent/GR3033332T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9702075A (pt) | 1998-06-09 |
| KR19980703718A (ko) | 1998-12-05 |
| DK0820284T3 (da) | 2000-07-24 |
| EP0820284A1 (en) | 1998-01-28 |
| ES2144844T3 (es) | 2000-06-16 |
| ZA97902B (en) | 1997-08-01 |
| GB9602721D0 (en) | 1996-04-10 |
| EA000166B1 (ru) | 1998-10-29 |
| ATE189388T1 (de) | 2000-02-15 |
| EA199700302A1 (ru) | 1998-04-30 |
| CA2217008A1 (en) | 1997-08-14 |
| AU1720097A (en) | 1997-08-28 |
| PT820284E (pt) | 2000-07-31 |
| US5859046A (en) | 1999-01-12 |
| EP0820284B1 (en) | 2000-02-02 |
| JPH11504041A (ja) | 1999-04-06 |
| HUP9900796A2 (hu) | 1999-07-28 |
| MX9707673A (es) | 1997-11-29 |
| NO974651L (no) | 1997-12-02 |
| NO974651D0 (no) | 1997-10-08 |
| PL322717A1 (en) | 1998-02-16 |
| DE69701243T2 (de) | 2000-09-07 |
| WO1997028796A1 (en) | 1997-08-14 |
| DE69701243D1 (de) | 2000-03-09 |
| GR3033332T3 (en) | 2000-09-29 |
| IL121808A0 (en) | 1998-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200000468A1 (ru) | Терапевтическая композиция для введения толтеродина с контролируемым высвобождением | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| RU94045155A (ru) | Способы ингибирования болезни альцгеймера | |
| DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
| ATE322283T1 (de) | Transdermale verwendung von sekretin zur behandlung von autismus | |
| ES2187575T3 (es) | Hexapeptidos ciclicos dotados de actividad antibiotica. | |
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| ES2074124T5 (es) | Composicion en forma de una espuma que contiene acido 5-aminosalicilico para administracion intra-rectal. | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| ES2094539T3 (es) | Preparacion farmaceutica y procedimiento para su preparacion. | |
| AR003427A1 (es) | Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas. | |
| KR890701587A (ko) | 골 손실에 관련된 질병 치료용 이미다조(1,2-a)(피리 | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| DE3575927D1 (de) | Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung. | |
| AR019496A1 (es) | Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos | |
| BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
| DE60138572D1 (de) | Methoden und pharmazeutische zusammensetzungen zur wundheilung | |
| IT1170214B (it) | Composizione farmaceutica per la cura delle arteriopatie periferiche | |
| ES2087623T3 (es) | Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon. | |
| ES2125696T3 (es) | Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales. | |
| ES2111352T3 (es) | Uso de diester fosfato para el tratamiento de enfermedades retinianas. | |
| ATE110723T1 (de) | Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung. | |
| AR005724A1 (es) | Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple | |
| MY104521A (en) | Treatment of depression. | |
| KR940013503A (ko) | 동맥경화증의 예방 또는 치료용 약제학적 조성물 |